SLC5A2 and hydrops fetalis: Pharmacologic therapy includes β-blockers, ACE inhibitors or angiotensin II receptor blockers (ARBs), ARNIs (e.g., sacubitril/valsartan), MRAs, diuretics, and SGLT2 inhibitors such as dapagliflozin and empagliflozin, which are now cornerstone therapies for HFrEF due to their proven benefits in reducing HF hospitalization and cardiovascular mortality.